Our industry clients commission us to orientate commercial, medical and leadership teams in new or existing therapy areas. They need to gain clinical insights to effectively launch new products and treatments. This is done by translating the clinical insights from our programs into enhanced market access, strategies, stakeholder identification and engagement activities, and product messaging. These programmes are often used to support new product launches or find new ways to maximise revenues from current treatment portfolios.
Our Disease-state programmes are perfect for those looking to gain a competitive advantage, using the programmes’ content to inform strategy, market access and system readiness, product messages and NHS stakeholder mapping and engagement.
Our Disease-state education programmes provide unrivalled levels of insights and authenticity into the therapy area, including:
- Treatment & patient pathways
- Decision-making processes
- Service KPIs and metrics
- Commissioning and tariff structures
- MDT simulations
- MDT roles and responsibilities – who and what influences who and what
Academy case study
The team really pay attention to the brief, they take the time to understand what our learning objectives are and they really work as a group to think collectively how can they maximise the events using the knowledge of all of the the people that are on hand and available to help us understand better.
I know that everybody that’s been here over the last couple of days will take that information into every single interaction that they have.
I think it’s just important for us to immerse ourselves into the customer’s reality, so the customers being our clinicians, but also, the patients.
It also gives us a really good opportunity to learn together as a team and to all be on the same baseline so we know exactly what we’re dealing with.
I think I’ve started to think about kidney cancer from a very different perspective, focusing on all the various healthcare professionals that patient may see, not necessarily just the small area that we can focus on, on our daily basis.
I think the course has been hugely beneficial for me, in my role, because I get much more of a huge sense now of how the multi-disciplinary team works for that patient, the number of healthcare professionals they may see in their in their treatment journey.
Within my role I focus very much on the end stage and the systemic treatment, but just seeing how much goes into that pathway before that systemic treatment is even really thought about and has just been incredible.
With this, it’s been, ‘can we keep going?’, ‘can we ask more questions?’, ‘can we find out a little bit more and dig a little bit deeper?’ because I think it’s everybody, no matter what their background’s been, has just found it so, so beneficial.
The event has been extremely slick in the way that it’s been organised.
The preparation that the team have put into to make sure that the content is appropriate for the audience has been incredible.
I think the way that the course has been run has been amazing, it’s been so smooth it’s been so professional but then also really relatable, I think, to anybody within the room, who, no matter what background they’ve come from, everything’s been explained so, so clearly, and, yeah, it’s been a really enjoyable experience.
The main things are taking away from this course are the case workload as well as the number of people who need to work in a team to make care as efficient as it can be for the patient.
I think I’ll take away mostly how multidisciplinary this treatment really is.
We speak, you know, been speaking to pathologists, urologists, oncologists, clinical specialists, it’s a real sense of all these specialties coming together.
I think the MDT session we observed really brought that to life.
I think the thing that I’ll take away the most is just the amount of teamwork that goes into all the decisions that are made from the whole multidisciplinary team, the amount of communication that requires, everybody is experts in their own rights but then sharing those expertise with their colleagues has just been absolutely incremental to the effect of patient care that has been going on.
I think for me, personally, what’s benefited me the most is I think within my role I focus very much on the end stage and the systemic treatment but just seeing how much goes into that pathway before that systemic treatment is even really thought about and has just been incredible, yeah.